Effect of canagliflozin on circulating active GLP-1 levels in patients with type 2 diabetes: a randomized trial.

Abstract

Canagliflozin has a robust inhibitory effect on sodium glucose transporter (SGLT)-2 and a mild inhibitory effect on SGLT1. The main purpose of this study was to investigate the effect of canagliflozin on circulating active glucagon-like peptide 1 (GLP-1) levels in patients with type 2 diabetes. Patients were randomly divided into a control group (n =15) and a canagliflozin-treated group (n =15). After hospitalization, the canagliflozin-treated group took 100 mg/day canagliflozin for the entire study, and after 3 days both groups took 20 mg/day teneligliptin for an additional 3 days. In a meal test, canagliflozin significantly decreased the area under curve (AUC) (0-120 min) for plasma glucose (PG) after 3 days when compared with that at baseline, and addition of teneligliptin to the canagliflozin-treated group further decreased it. A significant decrease in the AUC (0-120 min) for serum insulin by canagliflozin was obtained, but the addition of teneligliptin elevated the AUC, and thus abolished the significant difference from baseline. A significant increase in the AUC (0-120 min) of plasma active GLP-1 by canagliflozin-treatment compared with that at baseline was observed, and the addition of teneligliptin resulted in a further increase. However, canagliflozin-treatment did not change the AUC (0-120 min) of plasma active glucose-dependent insulinotropic peptide (GIP). In conclusions, canagliflozin-administration before meals decreased PG and serum insulin, and increased plasma active GLP-1 levels in patients with type 2 diabetes. Canagliflozin did not greatly influence plasma active GIP levels.

• Authors: Kohzo Takebayashi, Kenji Hara, Tomoko Terasawa, Rika Naruse, Mariko Suetsugu, Takafumi Tsuchiya, Toshihiko Inukai
• Journal: Endocrine journal (Endocr J) Vol. 64 Issue 9 Pg. 923-931 (Sep 30 2017) ISSN: 1348-4540 [Electronic] Japan
• PMID: 28824041 (Publication Type: Journal Article, Randomized Controlled Trial)

Chemical References

• Blood Glucose
• Hypoglycemic Agents
• Insulin
• Canagliflozin
• Gastric Inhibitory Polypeptide
• Glucagon-Like Peptide 1
• Glucagon

Topics

• Aged
• Blood Glucose
• Canagliflozin (therapeutic use)
• Diabetes Mellitus, Type 2 (blood, drug therapy)
• Female
• Gastric Inhibitory Polypeptide (blood)
• Glucagon (blood)
• Glucagon-Like Peptide 1 (blood)
• Humans
• Hypoglycemic Agents (therapeutic use)
• Insulin (blood)
• Male
• Middle Aged
• Treatment Outcome